Risks Versus Benefits of Different Types of Long-Acting Injectable Antipsychotics.
J Clin Psychiatry 2006;67(suppl 5):15-18
© Copyright 2016 Physicians Postgraduate Press, Inc.
Access to this article is available to valid users
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Register: If you do not have one already, register for a free account.
Since their introduction into clinical practice in the early 1960s, long-acting depot antipsychotics
have been widely used as maintenance therapy for patients with schizophrenia. The improved pharmacokinetics
of injectable long-acting antipsychotic therapies have provided more reliable drug delivery
and reduced differences in peak and trough plasma levels of the drug. Studies that have compared
short-acting oral antipsychotics with long-acting injectable antipsychotics, although imperfect,
support injectable antipsychotics as having real benefit over oral antipsychotics on patient outcome
owing largely to improved adherence. If patients forget or refuse to take their prescribed oral medications,
weeks or months may go by before they experience an exacerbation; the effects of nonadherence
become apparent too late to preempt the problem. On the other hand, if a patient fails to show up
for an injection, the problem of nonadherence can be immediately addressed. When injectable medication
is combined with an active psychosocial treatment program that will respond assertively to
nonadherence, relapse rates may be reduced. By preventing or delaying relapse, consistent treatment
can improve the patient’s quality of life and lead to an overall reduction in the cost of care.